US FDA approved biomarkers for BLC are becoming Gold standards for specifically targeted therapy. CPAF of NFCR aptly described; Imagine a patient having undergone expensive and painful chemotherapies for a couple of years unsuccessfully. All the while not knowing that tests like C.C.R.D.T., COXTEN & HTAS were available to signature profile the tumor. The use of GENE THERAPIES; Injection of Patients own retooled N-K cells with tumor DNA particles, can make BLC., a chronic but manageable disease. Thus stopping its potential for lethal spread. With speeded up translational research we could be able to use these modalities all the time.